M&A
Docker Separates Developer, Enterprise Businesses
By Chris Nolter
|
Published: November 14th, 2019
CEO Rob Bearden said Docker's businesses serving software developers and enterprises have "vastly different" product and financial models.
Insights & Analysis
Industry insights that are curated and delivered to inform your dealmaking strategies. We select the most relevant information, providing a consistent, convenient source for exclusive intelligence and analysis.
Page 37
M&A
Ladenburg, Advisor Group Ink Broker-Dealer Blockbuster
By Michael Brown
|
Published: November 14th, 2019
The $1.3 billion deal creates a broker-dealer with more than $450 billion in client assets and comes amid rapid consolidation in the field.
M&A
The Accidental Investment Banker
By David Marcus
|
Published: November 14th, 2019
In his new book 'How Money Became Dangerous,' former Salomon and Citi banker Chris Varelas takes a cynical if often hilarious view of finance.
M&A
Pfizer's Lankler Confirmed for Deal Economy Conference
By Armie Margaret Lee
|
Published: November 14th, 2019
On the heels of Pfizer's purchase of Array BioPharma and Therachon and its deal to combine its Upjohn unit with Mylan, the New York biopharmaceutical giant's general counsel is slated to speak at The Deal Economy Conference in New York on Nov. 20.
M&A
DOJ Clears BB&T-SunTrust With Significant Divestitures
By David Hatch
|
Published: November 12th, 2019
The sale of 28 banks in three states to First Horizon represents the largest bank merger divestiture in more than a decade.
M&A
AB InBev Gulps Up Craft Brew
By Paul Whitfield
|
Published: November 12th, 2019
AB InBev bid $221 million for the 68.8% it didn't already own in the Oregon-based boutique beer maker.
Activism
Financing Xerox's Bid for HP
By Chris Nolter
|
Published: November 9th, 2019
Can Xerox, with a market capitalization of $8.6 billion, really finance an acquisition of HP, with a $31.5 billion market cap?
M&A
FTC to Closely Examine Pfizer, Mylan Deal
By David Hatch
|
Published: October 29th, 2019
The transaction faces other regulatory hurdles, including a review by China, possible Brexit complications and clearances in nearly two dozen jurisdictions.
